Armata Pharmaceuticals (ARMP) Interest Expenses (2013 - 2026)
Armata Pharmaceuticals (ARMP) posted Interest Expenses of $58.4 million for Q1 2026, up 1108.05% sequentially from $4.8 million in Q4 2025, and up 1521.24% YoY from $3.6 million in Q1 2025.
Armata Pharmaceuticals (ARMP) Interest Expenses (2013 - 2026) Analysis & Trends
Armata Pharmaceuticals has reported Interest Expenses for 14 years, with the latest figure at $58.4 million in Q1 2026.
- Quarterly Interest Expenses rose 1521.24% year-over-year to $58.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $58.4 million (up 278.93% YoY) and the FY2025 annual result came in at $97.8 million, up 16.1% from the prior year.
- Interest Expenses rose to $58.4 million in Q1 2026 per ARMP's latest filing, from $4.8 million in the prior quarter.
- Over five years, Interest Expenses peaked at $69.6 million in Q2 2024 and troughed at $1452.0 in Q4 2022.
- A 5-year average of $17.5 million and a median of $4.8 million in 2025 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2022 and 2023: Interest Expenses plunged 99.93% in 2022, then soared 99762.26% in 2023.
- Over 5 years, Interest Expenses stood at $1452.0 in 2022, then jumped by 99762.26% to $1.4 million in 2023, then jumped by 383.03% to $7.0 million in 2024, then plunged by 30.98% to $4.8 million in 2025, then soared by 1108.05% to $58.4 million in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $58.4 million, $4.8 million, and $61.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Armata Pharmaceuticals | 182.82 Mn | 158.82 Mn | - | 6.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 57.07 Mn |
| Jun 30, 2026 | 57.07 Mn |
| Mar 31, 2026 | 58.40 Mn |
| Mar 31, 2026 | 58.40 Mn |
| Dec 31, 2025 | 4.83 Mn |
| Dec 31, 2025 | 4.83 Mn |
| Sep 30, 2025 | 61.00 Mn |
| Sep 30, 2025 | 61.00 Mn |
| Jun 30, 2025 | 5.62 Mn |
| Jun 30, 2025 | 5.62 Mn |
| Mar 31, 2025 | 3.60 Mn |
| Mar 31, 2025 | 3.60 Mn |
| Dec 31, 2024 | 7.00 Mn |
| Dec 31, 2024 | 7.00 Mn |
| Sep 30, 2024 | 66.12 Mn |
| Sep 30, 2024 | 66.12 Mn |
| Jun 30, 2024 | 69.64 Mn |
| Jun 30, 2024 | 69.64 Mn |
| Mar 31, 2024 | 3.36 Mn |
| Mar 31, 2024 | 3.36 Mn |